Telomir Pharms Stock Price, News & Analysis

Telomir Pharmaceuticals (NASDAQ:TELO) has announced breakthrough preclinical results for its drug Telomir-1 in prostate cancer treatment. The study revealed that Telomir-1 reduced tumor size by approximately 50% in a prostate cancer animal model using aggressive human prostate cancer cells.

Key findings show that Telomir-1 actively suppresses cancer growth and protects against chemotherapy-induced toxicity when combined with Paclitaxel. While Paclitaxel alone showed severe toxicity with one-third mortality in test animals, no deaths occurred when combined with low-dose Telomir-1.

The study also addressed concerns about telomere-elongating drugs potentially promoting cancer, demonstrating instead that Telomir-1 exhibits anti-cancer effects while benefiting healthy cells. The company is advancing Telomir-1 across multiple indications, including age-related macular degeneration and Wilson's disease, with plans to submit an Investigational New Drug application by year-end.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced breakthrough preclinical findings showing that Telomir-1 successfully reverses calcium dysregulation in multiple human cell lines. The study, using human keratinocyte and retinal cell lines, demonstrated that Telomir-1 restores calcium homeostasis within 10-20 minutes post-exposure and reverses oxidative stress while protecting mitochondrial integrity.

The research revealed that cells treated with Telomir-1 maintained viability despite exposure to extreme oxidative stress, while untreated cells showed degradation. The compound works by blocking calcium influx, preserving mitochondrial function, and preventing cell death pathways activation.

The study positions Telomir-1 as a potential therapeutic for multiple age-related conditions, including Alzheimer's disease, Age-related Macular Degeneration (AMD), Type 2 Diabetes, Wilson's disease, and viral-induced inflammatory conditions. The company is advancing preclinical studies to progress Telomir-1 toward human trials.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced a significant breakthrough in stabilizing both Silver(I) and Silver(II) ions using Telomir-1, making them biologically compatible for medical applications. This achievement addresses a major limitation in silver-based medical treatments.

The breakthrough opens opportunities in the silver wound dressings market, valued at $1.03 billion in 2024 and expected to reach $1.36 billion by 2030. The broader antimicrobial coatings market is projected to grow from $11.65 billion in 2024 to $33.7 billion by 2031, with a 14.2% CAGR.

Silver(II) offers enhanced healing properties compared to Silver(I), including stronger antimicrobial action, accelerated wound healing, and anti-inflammatory properties. The stabilization through Telomir-1 enables applications in burn care, chronic wound management, and medical device coatings.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced breakthrough results from preclinical studies of Telomir-1 in human retinal cell lines, showing significant reduction of copper and iron-induced Reactive Oxygen Species (ROS). The studies demonstrate potential treatment for Age-Related Macular Degeneration (AMD), a leading cause of blindness in adults over 50.

The research revealed that Telomir-1 effectively reduced ROS levels at low concentrations, suggesting regulatory properties rather than chelation effects. This indicates promising therapeutic potential for AMD treatment. The compound targets oxidative stress and metal-induced toxicity, key factors in AMD progression, offering a novel approach compared to current treatments that mainly manage symptoms.

The company plans to conduct AMD disease models to evaluate Telomir-1's efficacy in vivo, while also expanding research into other conditions including Wilson's disease, progeria, cancer, Alzheimer's, and infectious diseases.

Telomir Pharmaceuticals (NASDAQ:TELO) announced breakthrough results from preclinical studies showing Telomir-1's ability to fully reverse copper-induced elevation of Reactive Oxygen Species (ROS) and protect cells against copper toxicity in human cell lines. The compound demonstrated effectiveness at doses significantly lower than copper levels, indicating a unique regulatory mechanism beyond copper ion chelation.

The company is exploring Telomir-1's potential applications across multiple conditions where oxidative stress plays a important role, including Wilson's Disease, Alzheimer's, Age-related Macular Degeneration (AMD), cancer, and cardiovascular diseases. Additionally, Telomir is investigating the compound's potential as a treatment for viral infections, particularly avian influenza (bird flu), which has infected over 868 people globally with a 50% mortality rate according to WHO.

The research shows Telomir-1's ability to normalize ROS levels and provide cellular protection, positioning it as a promising therapeutic candidate for addressing oxidative stress-related pathologies and viral infections.

Telomir Pharmaceuticals (NASDAQ:TELO) announced breakthrough findings from a preclinical progeria lifespan study conducted with Nagi Bioscience SA. The study, using C. elegans models with wrn-1 gene mutation, demonstrated that Telomir-1 effectively restored lifespan and normalized accelerated aging effects to levels comparable with normal specimens.

The research focused on treating Progeria, a rare genetic condition affecting fewer than 400 children worldwide, causing rapid aging and premature death. Telomir-1, a novel small molecule, works by controlling excess metal activity, reducing oxidative stress, preventing ferroptosis, lowering inflammation, and regulating telomere shortening processes.

The company has demonstrated Telomir-1's therapeutic potential across multiple areas, including type 2 diabetes reversal and Wilson's disease treatment. Following these positive results, Telomir plans to initiate in vitro studies using human progeria cell lines to further validate the treatment's effectiveness.

Telomir Pharmaceuticals (NASDAQ:TELO) announced significant findings from copper binding studies with Telomir-1, expanding its potential application to Wilson's disease treatment. Preclinical studies showed Telomir-1's ability to bind copper, iron, and zinc ions. The company discontinued its planned osteoarthritis study in dogs due to ethical concerns and is pursuing a new study design with naturally affected elderly dogs.

The company is advancing multiple research initiatives, including studies in Wilson's disease, Type 2 diabetes, Progeria, cancer, and Alzheimer's. Telomir plans IND-enabling safety studies in Q2 2025, targeting IND submission by Q4 2025, with first-in-human trials expected in H1 2026. The company secured additional financing at a 20% premium with no warrants.

Telomir Pharmaceuticals (NASDAQ:TELO) has secured $1 million in equity funding through The Starwood Trust at $7 per share, representing a 20% premium to the closing price. The deal involves restricted common stock with no warrants and follows a previously secured $5 million non-dilutive credit line.

The company recently reported breakthrough preclinical results for Telomir-1, demonstrating age-reversal benefits and potential Type 2 diabetes treatment capabilities. The compound showed significant reductions in fasting plasma glucose levels and improved glucose homeostasis. Telomir-1 targets root causes of aging and disease, including oxidative stress, chronic inflammation, and telomere shortening.

The company is expanding research across multiple conditions, including Progeria, Alzheimer's Disease, Cancer, Wilson Disease, and Osteoarthritis.